Yaroslav Shparyk

Yaroslav Shparyk

Auto-generated profile, based on publicly available information

Yaroslav Shparyk

Department of Oncology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2021 in Proceeding of the Shevchenko Scientific Society. Medical Sciences
Verified
Journal Article
Open access
PDF file
NKNataliya Kitsera
Nataliya Kitsera
YSYaroslav Shparyk
Yaroslav Shparyk
LCLviv Lviv Oncological Regional Medical And Diagnostic Center
Lviv Lviv Oncological Regional Medical And Diagnostic Center
OTOrest Tril
Orest Tril
ZDZoriana Dvulit
Zoriana Dvulit
Cancer is the second leading cause of death worldwide. Aim of our study was to describe the spectrum of cancer among longlivers women in Lviv region (Ukraine) from database during 1991-2019. Material and methods. We studied 444 longlivers women aged 90+ who were diagnosed of cancer, treated and followed-up. Results. 104 women (23%) were diagnosed cancer to stage I, II -142 (32%), III -71 (10%), IV -57 (13%):other malignant neoplasms of skin (38.29%), breast (9.46%), colon (6.98%) and pancreas (4.95%) cancer. Diagnosis was confirmed cytology -169 (38.1%), histology-139 (31.3%). CT and MRI were used in rare cases in older women – 11(2.5%). Half of the women (227 or 51.13%) lived beyond 1 year after diagnosis. The rest is from 1 to 13 years. The relationship between life expectancy after diagnosis of cancer and type of treatment is weak (Сramer ratio ; Pearson's criterion ). Detected that the relationship between life expectancy after diagnosis and the age of patients at the time of oncologic diagnosis is weak too (Сramer ratio ; Pearson's criterion ). The relationship between life expectancy after diagnosis and stage of cancer is strong (Сramer ratio ; Pearson's criterion ). Conclusion. Aggressive anticancer treatments are less commonly used in cancer patients aged 90+, which may be one of the reasons for poorer survival due to comorbidities and natural causes. Life expectancy has relationship on the stage of the cancer, but does not have relationship on the age of the long-lived women and the type of treatment.

10 December 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SLSofiia Livshun
Sofiia Livshun
DKDenys Kozakov
Denys Kozakov
AKAlina Kruhlykovа
Alina Kruhlykovа
OKOlena Koshyk
Olena Koshyk
NKNazarii Kobyliak
Nazarii Kobyliak
OSOksana Sulaieva
Oksana Sulaieva
HER2-low breast cancer (BC) representing about 40–55% of all BC has emerged as a targetable entity. However, little is known about the link between germline BRCA1/2 mutations (gBRCA1/2) and HER2-low status in BC, especially in Ukrainian population. This study aims to elaborate on the rates of HER2-low status among patients with sporadic and BRCA1/2-associated hereditary BC in the Ukrainian population and investigate the relationship between gBRCA1/2 and HER2 status. This was a retrospective multicenter cross-sectional study on 1412 cases of BC. HER2 status was assessed according to ASCO-CAP Guidelines. All patients underwent germline NGS testing to detect SNV and indel variants in BRCA1 and BRCA2 genes. Overall, gBRCA1/2 genetic variants were found in 212 (15.0%) patients with BC. gBRCA1 variants were associated mostly with TNBC molecular subtype, while gBRCA2 mutations were linked to Luminal-like BC. The majority (343 of 436; 78.7%) of HER2-low BC was associated with luminal-like BC (P < 0.001). We also found significant relationships between gBRCA1/2 and HER2 status (P = 0.006). There were 837 HER2-zero (59.3%), 436 HER2-low (30.9%) and 139 HER2-positive (9.8%) BC. More than 70% of patients with gBRCA1 were HER2-negative. Alternatively, gBRCA2 cases possessed a higher rate of HER-low BC status (37.5%) as compared to WT (31.2%) and gBRCA1-associated BC (25.7%). In conclusion, gBRCA1 and gBRCA2 variants differed in their association with breast carcinoma molecular subtype and HER2-low status. gBRCA1 variants were linked to the prevalence of TNBC type and HER2 zero status. In contrast, gBRCA2 cases had a higher rate of HR + and HER-low breast cancer.

15 April 2020 in Proceedings of the Shevchenko Scientific Society. Medical Sciences
Verified
Journal Article
Open access
YSYaroslav Shparyk
Yaroslav Shparyk
MCMunicipal Non-Profit Enterprise Of Lviv Region Council
Municipal Non-Profit Enterprise Of Lviv Region Council
LCLviv Regional Oncology Treatment And Diagnostic Centre
Lviv Regional Oncology Treatment And Diagnostic Centre
The global spread of an infectious disease called COVID-19 which is caused by SARS-CoV-2. continues. The adverse course of COVID-19 is most often observed in patients with comorbidities, in particular malignant tumours. The application of active antineoplastic therapy (chemotherapy, immunotherapy, radiation exposure) can have a negative effect on the course of COVID-19. Therefore, systemic cancer treatment must account for the risk/benefit ratio. For each cancer patient, several factors, including age and comorbidities, and even the need to visit a hospital, may increase this risk. It is recommended to consider several variables, including the degree of the epidemic, capacities of local healthcare structures, the risk of patient's infection, the activity of malignancy, patient comorbidities, age, and treatment peculiarities. There are no simple and universal recommendations for providing cancer care during a crisis, and the inability to estimate the pandemic duration aggravates the issue. This literature review analyzes the experience of oncologists from different countries concerning diagnostic and therapeutic tactics for cancer patients during the pandemic. Practical recommendations on various types of tumours and treatment methods, determining priorities in the operation of oncological facilities, and rational use of financial and professional resources are considered.

30 May 2025 in Public Health Journal
Verified
Journal Article
Open access
PDF file
АГАндрій Михайлович Гриньків
Андрій Михайлович Гриньків
OBOlha Bas
Olha Bas
ФМФедір Васильович Музика
Федір Васильович Музика
МГМирослава Яківна Гриньків
Мирослава Яківна Гриньків
ЯШЯрослав Васильович Шпарик
Ярослав Васильович Шпарик
Актуальність. Хіміотерапія передбачає застосування лікарських засобів синтетичного чи природного походження (цитостатиків). Периферійна нейропатія, індукована хіміотерапією (далі – ПНІХ), виникає у 30–40 % хворих як тяжкий і тривалий побічний ефект. Мета. На основі аналізу літератури описати симптоми та порушення, обґрунтувати причини застосування засобів фізичної терапії в онкохворих у разі ПНІХ. Методи дослідження. Комплексне вивчення та аналіз наукових праць у наукових базах Scopus, Pub-Med, Google Scholar та ін.Результати дослідження. Симптоми ПНІХ призводять до функціональних труднощів, що погіршують повсякденну та соціальну активність, пацієнти відчувають проблеми з рухом, рівновагою і координацією, стають більш схильними до травм і мають більші ризики до падінь. Залежно від характеру ушкоджених нервових волокон виокремлюють три групи симптомів ПНІХ: сенсорні, моторні й вегетативні, прояви яких залежать від виду хіміотерапевтичного препарату. До хіміотерапевтичних препаратів, які чинять нейротоксичну дію на периферійну нервову систему, зараховують сполуки платини, таксани та алкалоїди барвінку, інгібітори протеасом та епотилони.Сенсорні симптоми можуть містити оніміння, поколювання, алодінію, гіпералгезію, парестезію, дизестезію, стріляючий біль, зміну або втрату відчуття вібрації та положення суглоба, порушення ходи й рівноваги, сенсорну атаксію. У важких випадках можлива повна втрата чутливості. Симптоми зазвичай починаються дистально й переміщуються проксимальніше, причому зазвичай спочатку вражаються стопи. Сенсорна нейропатія відмирання проявляється сенсорною парестезією за схемою «панчохи та рукавички». Моторні симптоми проявляються у вигляді периферійної слабкості, погіршення дрібної та великої моторики.Більшість симптомів зберігається, не піддається лікуванню і в багатьох випадках є незворотними, переходячи в хронічні стани. Висновки. Фізична терапія рекомендована як альтернативний немедикаментозний метод профілактики та зменшення побічної симптоматики й проявів ПНІХ під час та після проведеного лікування. З реабілітаційного та клінічного боків симптоми та важкість периферійної нейропатії об’єктивно оцінюють шляхом проведення клінічних обстежень, а також суб’єктивних вимірювань, як-от опитувальники й шкали.

16 December 2025 in Proceeding of the Shevchenko Scientific Society. Medical Sciences
Verified
Journal Article
Closed access
NKNataliya Kitsera
Nataliya Kitsera
IHIryna Hrytsay
Iryna Hrytsay
YSYaroslav Shparyk
Yaroslav Shparyk
TKTaras Kachmar
Taras Kachmar
DKDenys Kozakov
Denys Kozakov
NFNataliia Fesh
Nataliia Fesh
Prostate cancer (PCa) is one of the most common malignancies among men worldwide. Its etiology is multifactorial, but genetic variations play a critical role in disease development and progression, particularly mutations in BRCA1/2, HOXB13, ATM, CHEK2, and TP53. In Ukraine, PCa ranks as the second leading cause of cancer-related death and the most frequently diagnosed malignancy in males. A systematic search on PubMed, MEDLINE, Embase, Web of Science, Google Scholar, and CENTRAL (up to April 19, 2025) was conducted without language or date restrictions to identify studies on prostate cancer in adults (≥18 years) carrying HOXB13 and TP53 mutations, excluding other cancer types. A 68-year-old Ukrainian male presented in January 2020 with urinary symptoms and back pain. Digital rectal examination revealed an enlarged prostate with nodules. Biopsy confirmed acinar adenocarcinoma, Gleason score 8 (4+4). CT showed stage T4N1M1 disease with bone and retroperitoneal lymph node metastases. Family history revealed paternal lymphoma at the age of 71. Blood genetic testing identified HOXB13 c.251G>A (p.Gly84Glu) and TP53 c.581T>G (p.Leu194Arg) mutations. Over four years, the patient underwent orchiectomy, hormonal therapy, radiation and chemotherapy, but died of progressive PCa at the age of 72, 57 months after diagnosis. The coexistence of HOXB13 and TP53 mutations likely contributed to the aggressive tumor phenotype. HOXB13 variants are linked to hereditary and early-onset PCa, while TP53 mutations promote progression and therapy resistance. This case highlights the clinical value of genetic testing in aggressive prostate cancer and underscores the need for research into targeted therapies for genetically predisposed patients.

9 July 2025 in Exploration of Medicine
Verified
Journal Article
Open access
PDF file
NKNataliya Kitsera
Nataliya Kitsera
ZDZoriana Dvulit
Zoriana Dvulit
YSYaroslav Shparyk
Yaroslav Shparyk
OTOrest Tril
Orest Tril
Aim: To analyze cancer cases among male long-lived in the Lviv region (Ukraine) during 1991–2019. Methods: Our retrospective study analyzed cancer cases among 312 males aged 90+ from the Lviv region (Ukraine) during 1991–2019 using data from the Cancer Registry of Lviv Oncologic Regional Treatment and Diagnostic Center. Results: Among 312 long-lived men, 25 types of cancer were diagnosed (median age 92.5 ± 2 years): skin cancer (30.77%), prostate cancer (19.87%), and stomach cancer (7.69%) were the most common. A higher proportion of cancer patients lived in urban areas (72.12%) compared to rural areas (27.88%), indicating better healthcare access in urban areas, which may contribute to better survival rates. A strong negative correlation was found between age and survival duration, with a Pearson’s correlation coefficient (r) of −0.93. As age increases, the number of long-lived and the number of cancer diagnoses decreases, especially after age 93. Early-stage cancers (Stages 0 and I) showed significantly better survival outcomes, with 100% survival for 3–4 years in Stage 0, while Stage IV had a 78.13% mortality rate within one year, with no survivors beyond three years. For patients over 96, survival beyond one year is rare, indicating the need for a palliative care approach focused on symptom management rather than curative treatment. Conclusions: Future research should focus on improving early cancer detection for elderly patients, developing tailored treatments for aging individuals, and improving healthcare access for rural populations.